First trimester screening for Down syndrome using nuchal translucency, maternal serum pregnancy-associated plasma protein A, free-β human chorionic gonadotrophin, placental growth factor, and α-fetoprotein

2015 ◽  
Vol 35 (7) ◽  
pp. 709-716 ◽  
Author(s):  
Tianhua Huang ◽  
Alan Dennis ◽  
Wendy S. Meschino ◽  
Shamim Rashid ◽  
Ellen Mak-Tam ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Protein A ◽  
First Trimester ◽  
Nuchal Translucency ◽  
Maternal Serum ◽  
Placental Growth Factor ◽  
Chorionic Gonadotrophin ◽  
Human Chorionic Gonadotrophin ◽  
First Trimester Screening ◽  
Trimester Screening

Maternal serum placental growth factor and α -fetoprotein testing in first trimester screening for Down syndrome

2013 ◽  
Vol 33 (5) ◽  
pp. 457-461 ◽  
Author(s):  
Kim Donalson ◽  
Steve Turner ◽  
Lesley Morrison ◽  
Päivi Liitti ◽  
Christel Nilsson ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Growth Factor ◽  
First Trimester ◽  
Maternal Serum ◽  
Placental Growth Factor ◽  
First Trimester Screening ◽  
Trimester Screening

First-trimester screening for Down syndrome with ductus venosus Doppler studies in addition to nuchal translucency and serum markers

2005 ◽  
Vol 25 (10) ◽  
pp. 901-905 ◽  
Author(s):  
Antoni Borrell ◽  
Anna Gonce ◽  
Josep M. Martinez ◽  
Virginia Borobio ◽  
Albert Fortuny ◽  
...  
Keyword(s):  
Down Syndrome ◽  
First Trimester ◽  
Nuchal Translucency ◽  
Serum Markers ◽  
Ductus Venosus ◽  
Doppler Studies ◽  
First Trimester Screening ◽  
Trimester Screening

scholarly journals The effect of maternal alcohol and drug abuse on first trimester screening analytes: a retrospective cohort study

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Anni Lehikoinen ◽  
Raimo Voutilainen ◽  
Jarkko Romppanen ◽  
Seppo Heinonen
Keyword(s):  
Protein A ◽  
Serum Levels ◽  
First Trimester ◽  
Nuchal Translucency ◽  
Maternal Serum ◽  
Drug Abusers ◽  
Alcohol Abusers ◽  
Trimester Screening ◽  
Alcohol And Drug Abuse ◽  
Β Hcg

Abstract Background The purpose of this study was to determine whether first trimester trisomy screening (FTS) parameters are affected by alcohol and drug use. Methods A routine combined FTS including measurements of maternal serum levels of free β-human chorionic gonadotropin subunit (free β-hCG) and pregnancy-associated plasma protein A (PAPP-A) were measured at 9–11 weeks of gestation, and fetal nuchal translucency thickness (NTT) at 11–13 weeks of gestation. In total 544 women with singleton pregnancies [71 alcohol and drug abusers, 88 smokers, 168 non-smokers delivering a small for gestational age (SGA) child, and 217 unexposed control women] were assessed. Results Free β-hCG levels were higher in alcohol and drug abusing than in unexposed pregnant women [mean 1.5 vs. 1.2 multiples of medians (MoM); P = 0.013]. However, stepwise multiple linear regression analyses suggested that smoking could explain increased free β-hCG. Additionally, we observed lower PAPP-A levels in the smoking mothers (0.9 vs. 1.2 MoM; P = 0.045) and in those giving birth to an SGA child compared to the controls (1.1 vs.. 1.2 MoM; P < 0.001). Fetal NTT did not differ significantly between any of the groups. Conclusions The present study shows increased free β-hCG levels in alcohol and drug abusers, but maternal smoking may explain the result. Maternal serum PAPP-A levels were lower in smoking than non-smoking mothers, and in mothers delivering an SGA child. However, FTS parameters (PAPP-A, free β-hCG and NTT) seem not to be applicable for the use as alcohol biomarkers because of their clear overlap between alcohol abusers and healthy controls.

Sign in / Sign up

Export Citation Format

Share Document